• Nutlin-3a, MDM2, and GBM Ferroptosis Research

  2026-10-06

  A source-grounded overview of Nutlin-3a as an MDM2 inhibitor and its conceptual relevance to p53 signaling, ferroptosis, lipid metabolism, and glioblastoma research—without treating supplier claims or indirect evidence as clinical proof.

• RAB31 and the ESCRT-Independent Exosome Pathway

  2026-10-06

  The reference study identifies RAB31 as a regulator of an ESCRT-independent route for intraluminal vesicle formation and exosome secretion. Its central contribution is to connect EGFR signaling, flotillin-containing membrane domains, and RAB7-dependent lysosomal avoidance within one pathway, while also highlighting important limits on how broadly the mechanism should be generalized.

• L-Alanyl-L-Glutamine: Evidence and Research Context

  2026-10-05

  A source-grounded overview of L-Alanyl-L-glutamine, its proposed relevance to intestinal barrier research, and the limits of extrapolating from a separate MERS-CoV compound-screening study. The evidence supports careful conceptual investigation, but does not establish antiviral activity or clinical efficacy for the dipeptide.

• Nifedipine and the Calcium–Liver Translation Gap

  2026-10-05

  Nifedipine (BAY-a-1040) offers a pharmacological lens on calcium-dependent biology, but it should not be mistaken for a PXR activator. This thought-leadership analysis connects L-type calcium-channel research with liver regeneration, CYP activity, iron metabolism, and translational assay design while distinguishing evidence from hypothesis.

• Prodrug-Tethered LNPs for mRNA Cancer Immunotherapy

  2026-10-04

  The reference study introduces prodrug ionizable lipids that combine intracellular IDO-inhibitor release with IL-12 mRNA delivery in a single lipid nanoparticle platform. In a subcutaneous colon cancer mouse model, the lead formulation produced primary-tumor regression, reduced T cell exhaustion, promoted memory responses, and supported regression of distal tumors, while remaining limited to preclinical evidence.

• NEDD4L–PRMT5 Axis in Colorectal Liver Metastasis

  2026-10-03

  Dong et al. identify NEDD4L as a metastasis-suppressive E3 ubiquitin ligase in colorectal cancer and propose a mechanism involving PRMT5 degradation and inhibition of AKT/mTOR signaling. The study connects an in vivo E3-ligase screen with molecular validation, while its findings remain primarily preclinical and require confirmation across additional models and patient-derived material.

• Honeybee Smo Signaling and Olfactory Function

  2026-10-01

  Guo and colleagues identify and functionally characterize Smoothened in Apis mellifera, showing that pharmacological pathway modulation is associated with olfactory receptor expression, antennal electrophysiology, and odor-directed behavior. The study provides a useful insect model for investigating Hedgehog signaling in sensory biology while highlighting why Purmorphamine responses must be interpreted in a species- and endpoint-specific manner.

• PYR-41 and the Logic of E1-Controlled Immunity

  2026-10-01

  A translational guide to using PYR-41 as an E1-directed chemical probe, connecting ubiquitination control with NF-κB biology, inflammatory models, and the CD40–STING–TRAF2–IRF4 axis identified in esophageal squamous cell carcinoma.

• InstaBlue Protein Stain Solution for CRISPR Workflows

  2026-10-01

  See how InstaBlue Protein Stain Solution supports rapid protein electrophoresis analysis in CRISPR-Cas9 RNP and nanogel experiments. The workflow combines five-minute Coomassie visualization with orthogonal activity and release measurements, helping researchers verify sample integrity without adding fixation or solvent-heavy destaining steps.

• Tiamulin: Ribosome-to-Residue Safety Framework

  2026-09-30

  Tiamulin and Thiamutilin connect precise ribosomal inhibition with veterinary pharmacology, anti-inflammatory research, and ionophore-interaction risk. This guide translates molecular evidence into practical assay, exposure, and residue-control decisions.

• Pentoxifylline Workflows for Inflammation Research

  2026-09-29

  Build reproducible Pentoxifylline assays that connect cAMP elevation with macrophage activation, nitric oxide, and cytokine outcomes. This workflow-oriented guide also shows how to adapt the compound for psoriasis, motility, and in vivo inflammation studies without confusing exploratory applications with validated evidence.

• Pentoxifylline: From PDE Inhibition to Translation

  2026-09-29

  Pentoxifylline is more than a broad phosphodiesterase inhibitor: its cAMP-centered biology offers a practical framework for connecting inflammatory signaling, immune-cell behavior, sperm function, and translational assay design.

• Rucaparib and the Next DNA Damage Response

  2026-09-28

  Rucaparib (AG-014699, PF-01367338) offers translational researchers a precise way to interrogate PARP1-dependent repair, radiosensitization, transporter biology, and emerging links between DNA damage and transcriptional stress.

• Olsalazine Sodium: Workflows for Transport and Tumor Studies

  2026-09-28

  Use Olsalazine Sodium to investigate LTB4-linked macrophage chemotaxis, colorectal cancer biology, and xenobiotic handling—with distinct controls for each model. A 2025 mosquito study adds a useful warning: excretion changed with xenobiotic structure even when putative transporter expression changed little.

• Recombinant Human IL-15 for T-Cell Assays

  2026-09-27

  Build reproducible T-cell and NK-cell readouts with a defined, tag-free human cytokine and a practical dose-response workflow. This guide also explains how to use IL-15-supported cell assays alongside emerging RNA-based editing research—without confusing a culture reagent with a gene-editing component.

8061 records 1/538 page Next 12345 下5页 Last page